Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

Autor:	Silvin A; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France., Chapuis N; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France., Dunsmore G; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France., Goubet AG; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France., Dubuisson A; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France., Derosa L; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France., Almire C; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France., Hénon C; INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France., Kosmider O; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France., Droin N; INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France., Rameau P; INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France., Catelain C; INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France., Alfaro A; INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France., Dussiau C; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France., Friedrich C; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France., Sourdeau E; Service des Urgences, AP-HP, Hôpital Hôtel-Dieu, Paris 75014, France., Marin N; Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, Paris 75014, France., Szwebel TA; Service de Médecine Interne, AP-HP, Hôpital Cochin, Paris 75014, France., Cantin D; Service des Urgences, AP-HP, Hôpital Hôtel-Dieu, Paris 75014, France., Mouthon L; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service de Médecine Interne, AP-HP, Hôpital Cochin, Paris 75014, France., Borderie D; Service de Diagnostic Biologique Automatisé, AP-HP, Hôpital Cochin, Paris 75014, France., Deloger M; INSERM US23, CNRS UMS 3655, Gustave Roussy Cancer Campus, Villejuif 94800, France., Bredel D; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France., Mouraud S; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France., Drubay D; INSERM U1018, Gustave Roussy Cancer Campus, Villejuif 94800, France., Andrieu M; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France., Lhonneur AS; Laboratoire de Virologie, AP-HP, Hôpital Cochin, Paris 75014, France., Saada V; Département de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France., Stoclin A; Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France., Willekens C; INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Hématologie, Gustave Roussy Cancer Campus, Villejuif 94800, France., Pommeret F; Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France., Griscelli F; Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département de Biologie et Pathologie, Gustave Roussy Cancer Campus, Villejuif 94800, France., Ng LG; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos Building #3-4, Biopolis, Singapore 138648, Singapore., Zhang Z; Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province, China., Bost P; Systems Biology Group, Department of Computational Biology and USR 3756, Institut Pasteur and CNRS, Paris 75015, France; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Amit I; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel., Barlesi F; Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France., Marabelle A; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy Cancer Campus, Villejuif 94800, France., Pène F; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, Paris 75014, France., Gachot B; Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France., André F; Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; INSERM U981, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France., Zitvogel L; INSERM U1015, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France; Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, Villejuif 94800, France., Ginhoux F; Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos Building #3-4, Biopolis, Singapore 138648, Singapore; Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China; Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore. Electronic address: florent_ginhoux@immunol.a-star.edu.sg., Fontenay M; Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris 75006, France; Service d'Hématologie Biologique, AP-HP, Hôpital Cochin, Paris 75014, France. Electronic address: michaela.fontenay@aphp.fr., Solary E; INSERM U1287, Gustave Roussy Cancer Campus, Villejuif 94800, France; Service de Réanimation Médicale, Gustave Roussy Cancer Campus, Villejuif 94800, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre 94270, France. Electronic address: eric.solary@gustaveroussy.fr.
Jazyk:	angličtina
Zdroj:	Cell [Cell] 2020 Sep 17; Vol. 182 (6), pp. 1401-1418.e18. Date of Electronic Publication: 2020 Aug 05.
DOI:	10.1016/j.cell.2020.08.002
Abstrakt:	Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with disease severity and whether markers of innate immunity discriminate high-risk patients. Thus, we performed high-dimensional flow cytometry and single-cell RNA sequencing of COVID-19 patient peripheral blood cells and detected disappearance of non-classical CD14 Low CD16 High monocytes, accumulation of HLA-DR Low classical monocytes (Human Leukocyte Antigen - DR isotype), and release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10 Low CD101 - CXCR4 +/- neutrophils with an immunosuppressive profile accumulated in the blood and lungs, suggesting emergency myelopoiesis. Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation. Competing Interests: Declaration of Interests A. Silvin, N.C., M.F., E. Solary, and F. Ginhoux are inventors of patent EP 20305624.7, “Methods for detecting and treating COVID patients requiring intensive care,” submitted on June 9, 2020 under Gustave Roussy. (Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu